ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

ADAP Advocacy Names William Sarraille as Special Counsel for 340B Issues





Sarraille is a nationally recognized expert in health care, life sciences, drugs, medical devices, and patient access to treatments

WASHINGTON, DC, February 06, 2025 /24-7PressRelease/ -- ADAP Advocacy today announced that William "Bill" Sarraille will serve as Special Counsel on issues related to the 340B Drug Pricing Program. Sarraille will advise the organization, and its 340B Patient Advisory Committee, on 340B public policy, federal and state legislative and regulatory matters, and efforts to reform the program to better serve patients.

Brandon M. Macsata, CEO of ADAP Advocacy, summarized: "Bill's insights on the 340B Program are legendary among healthcare public policy stakeholders because he understands the legislative intent of the law, as well as current and emerging trends with the program, and why the real-life application of the program's explosive growth is not helping underserved patients. He has been yelling from the rooftop asking why sick patients are paying cost sharing amounts to enormously profitable, large 340B hospitals, some with endowments in the hundreds of millions of dollars? We share that sentiment and our alignment on the need to return the program to its original legislative intent makes this a match made in Heaven."

Bill Sarraille is widely known for his expertise in a broad array of healthcare matters, including Medicare and Medicaid reimbursement, coverage and coding, pharmaceutical price reporting, issues related to the marketing and promotion of pharmaceuticals and medical devices, clinical research issues, Stark and Anti-Kickback Law compliance, Medicare and Medicaid audits, healthcare privacy and security, and coverage for new devices and services. Bill also serves as an independent director at Kalderos, Inc. Learn more about Bill Sarraille.

To learn more about ADAP Advocacy or the 340B Drug Pricing Program, please email info@adapadvocacy.org.

About ADAP Advocacy: ADAP Advocacy's mission is to promote and enhance the AIDS Drug Assistance Programs (ADAPs) and improves access to care for persons living with HIV/AIDS. ADAP Advocacy works with advocates, community, health care, government, patients, pharmaceutical companies, and other stakeholders to raise awareness, offer patient educational programs, and foster greater community collaboration.

---
Press release service and press release distribution provided by https://www.24-7pressrelease.com

Recent Quotes

View More
Symbol Price Change (%)
AMZN  227.35
+0.59 (0.26%)
AAPL  273.67
+1.48 (0.54%)
AMD  213.43
+12.37 (6.15%)
BAC  55.27
+1.01 (1.86%)
GOOG  308.61
+4.86 (1.60%)
META  658.77
-5.68 (-0.85%)
MSFT  485.92
+1.94 (0.40%)
NVDA  180.99
+6.85 (3.93%)
ORCL  191.97
+11.94 (6.63%)
TSLA  481.20
-2.17 (-0.45%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.